On the subject in the title: Managing an unplanned gap in supply — what changed since Working notes rather than a conclusion.
What changes if the standard account of Managing an unplanned gap is wrong? I ask because I have been treating it as settled and I noticed this week that I could not say why.
Working through the consequences rather than the evidence, since others here are better placed on the evidence.
Practical answer on Managing an unplanned gap, since the theoretical one is upthread: do the simplest check first, write down the result, and only then decide whether the complicated explanation is needed. It usually is not.
Agreed on all of that, and I have nothing to add to it.
Answering the question the opening post raises rather than the one it answers.
Adding a reference point for Managing an unplanned gap. Mine is a single case, collected without controls, and I am posting the method alongside it so it can be discounted appropriately.
Managing an unplanned gap: if a shortage causes a gap in treatment, the questions are how long the gap will be and how that affects your condition. Discussing with your clinician is prudent if the gap is weeks or longer.
A qualification I should have led with rather than closed on.
Post #4 describes the usual case. This is about the unusual one.
One more thing on Managing an unplanned gap that took me far too long to see: the two figures people quote are not measuring the same quantity. Once you notice that, the apparent contradiction disappears.
I had written a reply contradicting post #8 and deleted it. Here is what survived.
Where the Managing an unplanned gap discussion usually stalls is that nobody wants to say "I do not know" and everyone is willing to say "it varies". Those are the same sentence with different clothes on.
Confirming post #11 from a second method, which matters more than confirming it from a second person.
Both are useful and different. The notice tells you the national position; the account tells you what is happening on the ground.
Worth reading the earlier posts in this thread before acting on mine.
Resuming after a gap: after a gap of days or a few weeks, most people resume at the dose they were on when they stopped. Gaps of months might require retitration discussion with a clinician.
A single observation, in a thread that deserves better than single observations.
International supply chains: a shortage in one country does not mean shortage in another. That is why ordering from multiple suppliers before a shortage gets bad is prudent if you can.
On post #15 — agreed on the reasoning, with one qualification.
Where a shortage forces a gap, the pharmacokinetics mean a missed week is a perturbation rather than a reset, which is worth knowing.
That is one dataset and I would not build a rule on it.
Thank you for taking the time. That was more work than a reply usually is.
That matches what I have seen, for whatever a single anecdote is worth.
Supply interruptions: official shortage notices are published by regulatory agencies. That is the correct primary source rather than pharmacy rumors or forum discussion.
My experience of Managing an unplanned gap contradicts the reply above. I am posting it as a data point rather than as a refutation, because one person's experience is exactly that.
Post #20 and I disagree about the size of the effect, not about the direction.
Where a manufacturer publishes a supply statement, that document is more reliable than any aggregation of individual experiences.
Two people can read the same figure differently here and both be reasonable.
Device availability and compound availability are separate supply chains and the device is frequently the constraint.
This follows post #24 rather than contradicting it.
I would put moderate confidence on the mainstream reading of Managing an unplanned gap and no more. That is not scepticism for its own sake; it is where the sourcing actually stops.
Worth separating two things that post #22 runs together.
The published shortage register maintained by the national regulator is the authoritative source here, and it is updated far more often than any thread.
Not a conclusion. A place to stand while looking for one.
Dose hold versus tapering: if a temporary shortage forces a gap, holding your dose and resuming when supply returns is different from gradually tapering. The two are different decisions.
Managing an unplanned gap: if a shortage causes a gap in treatment, the questions are how long the gap will be and how that affects your condition. Discussing with your clinician is prudent if the gap is weeks or longer.
Not a strong opinion, just a consistent one.
Worth separating Managing an unplanned gap as a question about the compound from Managing an unplanned gap as a question about the documentation. They get answered by different people and only one of them is answerable here.